↓ Skip to main content

Off-label use of Baricitinib improves moderate and severe atopic dermatitis in China through inhibiting MAPK and PI3K/Akt/mTOR pathway via targeting JAK-STAT signaling of CD4+ cells

Overview of attention for article published in Frontiers in Pharmacology, February 2024
Altmetric Badge

Mentioned by

twitter
1 X user

Readers on

mendeley
6 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Off-label use of Baricitinib improves moderate and severe atopic dermatitis in China through inhibiting MAPK and PI3K/Akt/mTOR pathway via targeting JAK-STAT signaling of CD4+ cells
Published in
Frontiers in Pharmacology, February 2024
DOI 10.3389/fphar.2024.1324892
Pubmed ID
Authors

Shuang Chen, Caihua Li, Zeng Tu, Tao Cai, Xinying Zhang, Lei Wang, Ruoyuan Tian, Jinglan Huang, Yuxuan Gong, Xiaotong Yang, Zetong Wu, Sirong He, Wenyan He, Dan Wang

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 6 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 6 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 4 67%
Other 1 17%
Student > Doctoral Student 1 17%
Readers by discipline Count As %
Economics, Econometrics and Finance 4 67%
Pharmacology, Toxicology and Pharmaceutical Science 1 17%
Engineering 1 17%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 February 2024.
All research outputs
#22,774,430
of 25,387,668 outputs
Outputs from Frontiers in Pharmacology
#12,413
of 19,728 outputs
Outputs of similar age
#119,888
of 149,772 outputs
Outputs of similar age from Frontiers in Pharmacology
#122
of 384 outputs
Altmetric has tracked 25,387,668 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 19,728 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 149,772 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 384 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.